The Goldman Sachs Group Cuts Charles River Laboratories International (NYSE:CRL) Price Target to $190.00

Charles River Laboratories International (NYSE:CRL) had its price objective cut by The Goldman Sachs Group from $220.00 to $190.00 in a report published on Thursday morning,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

Other equities research analysts have also recently issued research reports about the stock. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a research report on Monday, November 18th. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday. Citigroup cut Charles River Laboratories International from a “neutral” rating to a “sell” rating and dropped their target price for the company from $215.00 to $175.00 in a report on Tuesday, October 1st. Finally, TD Cowen lifted their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $204.38.

Charles River Laboratories International Stock Down 1.2 %

Shares of NYSE:CRL opened at $164.88 on Thursday. The firm has a market capitalization of $8.43 billion, a PE ratio of 20.64, a price-to-earnings-growth ratio of 5.94 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. Charles River Laboratories International has a 52-week low of $160.85 and a 52-week high of $275.00. The firm has a fifty day moving average of $186.75 and a 200 day moving average of $197.21.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the prior year, the business earned $2.72 EPS. As a group, research analysts anticipate that Charles River Laboratories International will post 10.18 EPS for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Hedge funds have recently made changes to their positions in the company. Empirical Finance LLC lifted its position in Charles River Laboratories International by 4.2% during the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock valued at $258,000 after buying an additional 53 shares during the period. American Trust lifted its position in Charles River Laboratories International by 5.9% during the 2nd quarter. American Trust now owns 976 shares of the medical research company’s stock valued at $202,000 after acquiring an additional 54 shares during the period. OLD National Bancorp IN boosted its stake in Charles River Laboratories International by 3.1% during the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock worth $392,000 after acquiring an additional 59 shares in the last quarter. Fiduciary Financial Group LLC grew its holdings in Charles River Laboratories International by 3.9% in the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock worth $310,000 after purchasing an additional 63 shares during the period. Finally, Pinnacle Bancorp Inc. increased its stake in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).